BNTX — BioNTech SE Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	18,977	17,311	3,819	2,751	2,870
Cost of Revenue
Gross Profit	16,065	14,316	3,219	2,336	2,421
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,693	4,668	3,129	4,065	4,275
Operating Profit	15,284	12,643	690	-1,314	-1,405
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	15,046	12,954	1,186	-678	-1,051
Provision for Income Taxes
Net Income After Taxes	10,293	9,434	930	-665	-1,136
Net Income Before Extraordinary Items
Net Income	10,293	9,434	930	-665	-1,136
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10,293	9,434	930	-665	-1,136
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	39.3	37.8	3.95	-0.428	-1.46
Special Dividends per Share